In this week’s issue:
- Alzheimer’s Drug Discovery Foundation – Biomarker Trials
- Immune Tolerance Network – Trials of Transplantation Therapies
- Blueline Bioscience – Blueline Drug Target Program
- World Federation of Hemophilia – Clinical Research Program
- Families of SMA – Research Projects on Spinal Muscular Atrophy
- Canadian Blood Services – 2014 Kenneth J. Fyke Award
- Digital Science – Lunch and Learn
- UBC Faculty of Medicine Continuing Professional Development – UBC Radiology Conference Vancouver Imaging Review: Head to Toe
LOI Deadline: August 22, 2014
The Alzheimer’s Drug Discovery Foundation and the Alzheimer’s Disease Cooperative Study are collaborating to support pilot biomarker-based clinical trials of novel therapeutics for Alzheimer’s disease.
Through this grant initiative, ADDF and ADCS will provide funding and resources to one or more clinical trials. Priority will be given for therapeutics whose target engagement can be directly assessed in humans using serial cerebrospinal fluid sampling. In addition to funding, ADCS will contribute resources and infrastructure for data management, quality control, and statistics support. ADCS also will offer access to unique biomarker assays including the SILK technology, if appropriate.
Applications may be submitted by nonprofit academic institutions and for-profit biotechnology companies, both public and private, worldwide. Successful applicants will be contacted by the foundation with instructions for submitting a full proposal, which will be due September 5.
Visit the ADDF website for complete program guidelines and LOI submission instructions.
LOI Deadline: August 29, 2014
The Immune Tolerance Network is an international clinical research consortium founded by the National Institute of Allergy and Infectious Disease. ITN develops, implements, and conducts trials of novel immune tolerance therapeutics for Type 1 Diabetes, autoimmune diseases, transplantation, and allergy and asthma.
To support this mission, the network has issued a Request for Proposals for clinical tolerance trials in transplantation using solid organs or islets from deceased donors. Preference will be given to trials with a testable mechanism of tolerance induction and a strategy for assays investigating this mechanism. ITN is particularly interested in proposals for phase II trials that involve between five and thirty patients.
Proposals are welcome from academic, government, and industry-based investigators. Funding amounts will vary based on the type and scope of the trial.
Letters of Inquiry must be received no later than August 29, 2014. Upon review, selected applicants will be invited to submit full proposals in early September 2014, which will be due in early October 2014.
Visit the ITN website for complete program guidelines and LOI submission instructions.
LOI Deadline: August 29, 2014
The Blueline Bioscience Drug Target Program is open to independent researchers at any Canadian research institution and will provide up to $150,000 for one year to successful applicants to support the validation of promising therapeutic targets in specific areas of interest. The objectives of the program are:
- To advance the validation of novel drug targets and/or lead compounds
- To forge collaborations between the leading academic researchers, biotechnology entrepreneurs, and life science investors to validate novel therapeutic targets and/or lead compounds;
- To identify academic projects with very high commercial potential for drug development in the therapeutic fields of interest; and
- To ultimately create biotech companies to progress these discoveries toward commercialization.
Further details on the Program and Application Process can be found on-line at: http://www.bluelinebio.com/grants
LOI Deadline: August 31, 2014
The World Federation of Hemophilia is accepting Letters of Intent for international clinical research projects relating to inherited bleeding disorders.
Through its Clinical Research Grant Program, WFH will award grants of up to $50,000 to support investigations designed to create better evidence for the clinical management of hemophilia A and B, von Willebrand disease, rare factor deficiencies, and inherited platelet disorders.
The program is open to applicants from all countries who are affiliated with a recognized medical, scientific, or academic institution; hemophilia or inherited bleeding disorder treatment center; or WFH National Member Organization or its affiliated chapters. Ph.D. students are not eligible; the principal investigator must hold a faculty position at a recognized medical, scientific, or academic institution.
LOIs must be received by August 31, 2014. Selected applicants will be notified and invited to submit a full proposal (maximum five pages) in English by December 1.
Visit the WFH website for complete program guidelines and LOI submission instructions.
Deadline: September 5, 2014
Families of SMA funds and directs research programs that seek to develop a treatment and cure for Spinal Muscular Atrophy disease, a hereditary disease that cause weakness and wasting of the voluntary muscles in the arms and legs of infants and children. To date, the charity has invested over $55 million in research and has been involved in funding almost two-thirds of all ongoing novel drug programs for this disease.
Families of SMA has issued a Request for Proposals for research projects designed to advance current understanding of Spinal Muscular Atrophy disease. Grants of up to $150,000 will be awarded for novel research related to SMA disease pathology at the molecular, cellular, and biochemical level; generate key reagents and tools to facilitate drug development and clinical trials; and identify new therapeutic strategies for SMA.
To be considered, studies should focus on the molecular and biochemical mechanisms regulating SMN expression or mediating SMN function; result in greater understanding of the pathophysiology of SMA, using well-validated animal or cellular models; provide early proof-of concept assessment of novel therapeutic approaches for SMA in well-validated animal or cellular models; and/or focus on generating research and clinical trial tools, such as new animal models for SMA, phenotypic cellular assays for SMA, biomarkers or outcome measures for SMA clinical trials, newborn screening protocols, and others.
Visit the Families of SMA website for complete program guidelines and application information.
Deadline: October 1, 2014
Canadian Blood Services is pleased to announce the 2014 Kenneth J. Fyke Award competition.
The Kenneth J. Fyke Award program supports health services and policy research in order to promote the development of evidence-based Canadian practices and policies in blood
transfusion, blood stem cell transplantation, and organ and tissue transplantation for the benefit of Canadian patients.
The Kenneth J. Fyke Award will support one project with up to $100,000 for a period of one year.
Digital Science – Lunch and Learn
Date & Time: August 11, 2014, 1pm
Location: Sherrington Room, Woodward Library, 2198 Health Sciences Mall
Interested in a free lunch? Curious about technology tools that can accelerate your research?
Please join us to learn about the various “state-of-the-art software” from Digital Science.
The UBC Library is excited about bringing Digital Science to UBC to show a range of new software tools that are designed through collaborations with researchers worldwide to improve the research process.
Check out their website http://www.digital-science.com/ and join us for lunch. Bring your questions and your curiosity.
Please see attachment for further details.
Date: September 18-21, 2014
Location: Rosewood Hotel Georgia, 801 W. Georgia St., Vancouver BC
The UBC Vancouver Imaging Review is designed to provide participants with the necessary tools to enhance their interpretation skills utilizing the latest imaging technologies including MR, MDCT, PET/CT, Ultrasound and Radiography. The lectures will review protocols, techniques, evidence-based literature, pearls and pitfalls to help participants improve their diagnostic accuracy in neuro, breast, gynecologic, pediatric, emergency/trauma, musculoskeletal, thoracic, cardiac and oncologic imaging applications.